Authors: O'Day, SJ Boasberg, PD Kristedja, TS Martin, M Wang, HJ Fournier, P Cabot, M DeGregorio, MW Gammon, G

Citation: Sj. O'Day et al., High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma, CANCER, 92(3), 2001, pp. 609-619

Authors: O'Day, SJ Gammon, G Boasberg, PD Martin, MA Kristedja, TS Guo, M Stern, S Edwards, S Fournier, P Weisberg, M Cannon, M Fawzy, NW Johnson, TD Essner, R Foshag, LJ Morton, DL

Citation: Sj. O'Day et al., Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma, J CL ONCOL, 17(9), 1999, pp. 2752-2761